1、1 On the Cusp of a CureIs Asia Pacific Ready for the Precision Era?South KoreaL.E.K.Consulting is a registered trademark of L.E.K.Consulting LLC.All other products and brands mentioned in this document are properties of their respective owners.2025 L.E.K.Consulting LLC1 L.E.K.Consulting|On the Cusp
2、of a CureOn the Cusp of a CureIs Asia Pacific Ready for the Precision Era?2 L.E.K.Consulting|On the Cusp of a CureAcknowledgements L.E.K.Consulting would like to acknowledge the contributions of all the Advisory Committee members who have provided critical insights into the development of this repor
3、t.Specifically,their contributions have guided the assessment of barriers facing the adoption of precision therapies and recommendations to addressing these barriers.NamePositionOrganisation AustraliaDavid ThomasChief Scientific OfficerOmicoJaala PulfordChair of the BoardMTPConnectChristine Cockburn
4、CEORare Cancers AustraliaChinaBaorong YuProfessor and market access key opinion leaderUniversity of International Business and EconomicsAndy MokHead of ChinaGuardant HealthKevin HuangFounder and PresidentChina Organization for Rare Disorders(CORD)Zhou CaicunProfessor and lung cancer key opinion lead
5、erSchool of Medicine,Tongji UniversityJapanTeruyuki KatoriRepresentative Director Specially Appointed ProfessorFuture Institute Wolong,General Incorporated Association Graduate School of Social Sciences,University of HyogoDaisuke SatoProfessorFujita Health universityManabu MutoProfessorKyoto Univers
6、ity Graduate School of MedicineMasahiro MiyakeProfessorKyoto University HospitalNaomi SakuraiFounder and CEOCancer Solutions Keisuke ShimizuLeader Lung cancer HER2 HER HERSouth KoreaPaul LeeFormer GMGilead Sciences KoreaJin-Ah KimAdvocate for rare diseasesSeoul National University Hospital,Departmen